Recital 2, Regulation (EU) 2024/3169

In forcesince 18 Dec 2024

Pursuant to Article 16(1) of Regulation (EU) 2021/2282, the Coordination Group is to carry out joint scientific consultations in order to exchange information with health technology developers on their development plans for a medicinal product for human use (‘medicinal product’). The aim of such consultations is to facilitate the process of preparing joint clinical assessments for medicinal products, as they will allow health technology developers to obtain guidance from the Coordination Group on the information, data, analyses and other evidence that are likely to be required from clinical studies for the joint clinical assessment of those medicinal products.